Skip to main content
NCD 110.10 · version 1

NCD 110.10: Intravenous Iron Therapy

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026). Next CMS release: weekly, every Thursday.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 110.10

Benefit category
Drugs and Biologicals
Effective date
10/01/2001
Implemented 10/01/2001
Transmittal
Transmittal 139
Versions published
1
Manual section
110
Hematology/Immunology/Oncology, NCD Manual (Pub. 100-03) chapter 1 part 2

TL;DR

NCD 110.10 sets Medicare's national policy for intravenous iron therapy under the benefit category "Drugs and Biologicals", effective 10/01/2001 and implemented 10/01/2001. Effective December 1, 2000, Medicare covers sodium ferric gluconate complex in sucrose injection as a first line treatment of iron deficiency anemia when furnished intravenously to patients undergoing chronic hemodialysis who are receiving supplemental… It has been revised once since publication and binds every Medicare Administrative Contractor nationally.

Item or service described

Iron deficiency is a common condition in end stage renal disease (ESRD) patients undergoing hemodialysis. Iron is a critical structural component of hemoglobin, a key protein found in normal red blood cells (RBCs) which transports oxygen. Without this important building block, anemic patients experience difficulty in restoring adequate, healthy RBCs that improve hematocrit levels. Clinical management of iron deficiency involves treating patients with iron replacement products while they undergo hemodialysis. Body iron stores can be supplemented with either oral or intravenous (IV) iron products. The available evidence suggests that the mode of intravenous administration is perhaps the most effective treatment for iron deficiency in hemodialysis patients. Unlike oral iron products which must be absorbed through the GI tract, IV iron products are infused directly into the bloodstream in a form that is readily available to the bone marrow for RBC synthesis, resulting in an earlier correction of iron deficiency and anemia.

Indications and limitations of coverage

Effective December 1, 2000, Medicare covers sodium ferric gluconate complex in sucrose injection as a first line treatment of iron deficiency anemia when furnished intravenously to patients undergoing chronic hemodialysis who are receiving supplemental erythropoeitin therapy.

Effective October 1, 2001, Medicare also covers iron sucrose injection as a first line treatment of iron deficiency anemia when furnished intravenously to patients undergoing chronic hemodialysis who are receiving supplemental erythropoeitin therapy.

Text reproduced from the CMS Medicare Coverage Database record for NCD 110.10 version 1. View the original on cms.gov.

Local policies that build on this NCD

7 active Local Coverage Determinations cite NCD 110.10 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.

  • Frequency of Hemodialysis (L37537) · Wisconsin Physicians Service Insurance Corporation
  • L34575 Frequency of Hemodialysis · Palmetto GBA
  • L35014 Frequency of Hemodialysis · Novitas Solutions, Inc.
  • L37475 Frequency of Hemodialysis · Wellpoint Federal
  • L37502 Frequency of Hemodialysis · Noridian Healthcare Solutions, LLC
  • L37564 Frequency of Hemodialysis · First Coast Service Options, Inc.
  • L37575 Frequency of Hemodialysis · CGS Administrators, LLC

How MACs bill NCD 110.10

A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 3 current articles in the Medicare Coverage Database name NCD 110.10, 3 of them with a covered ICD-10-CM list, from 3 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.

Contractors with articles that implement NCD 110.10
ContractorArticles
First Coast Service Options, Inc.A56666
Noridian Healthcare Solutions, LLCA55675
Wellpoint FederalA55672

A55672: Billing and Coding: Frequency of Hemodialysis

Billing and Coding, effective 2026-04-01 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record

56 covered ICD-10-CM codes; 1 procedure code: 90999. Local policy: L37475 Frequency of Hemodialysis. Check a diagnosis for 90999.

First covered codes: E83.30 Disorder of phosphorus metabolism, unspecified; E83.39 Other disorders of phosphorus metabolism; E87.20 Acidosis, unspecified; E87.21 Acute metabolic acidosis; E87.22 Chronic metabolic acidosis; E87.29 Other acidosis; …

A55675: Billing and Coding: Frequency of Hemodialysis

Billing and Coding, effective 2025-10-16 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

56 covered ICD-10-CM codes; 1 procedure code: 90999. Local policy: L37502 Frequency of Hemodialysis. Check a diagnosis for 90999.

First covered codes: E83.30 Disorder of phosphorus metabolism, unspecified; E83.39 Other disorders of phosphorus metabolism; E87.20 Acidosis, unspecified; E87.21 Acute metabolic acidosis; E87.22 Chronic metabolic acidosis; E87.29 Other acidosis; …

A56666: Billing and Coding: Frequency of Hemodialysis

Billing and Coding, effective 2023-01-01 · First Coast Service Options, Inc. (09101, 09102, 09201, 09202, 09302) · CMS record

55 covered ICD-10-CM codes; 1 procedure code: 90999. Local policy: L37564 Frequency of Hemodialysis. Check a diagnosis for 90999.

First covered codes: E83.30 Disorder of phosphorus metabolism, unspecified; E83.39 Other disorders of phosphorus metabolism; E87.21 Acute metabolic acidosis; E87.22 Chronic metabolic acidosis; E87.29 Other acidosis; E87.5 Hyperkalemia; …

Coverage analysis history

CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links 2 analyses to NCD 110.10, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.

  1. CAG-00046N Ferrlecit®: Intravenous Iron Therapy (New, Closed)
  2. CAG-00080N Venofer: Intravenous Iron Therapy (New, Closed)

Revision history

01/2021 - Transmittal 10515, dated December 10, 2020, is being rescinded and replaced by Transmittal 10566, dated, January 14, 2021 to remove FISS Reason Codes (RCs) 59041, 59042, 59209, and 59210 from the spreadsheet for NCD 160.18. All other information remains the same. ( TN 10566 ) (CR12027)

12/2020 - This Change Request (CR) constitutes a maintenance update of ICD-10 conversions and other coding updates specific to NCDs. These NCD coding changes are the result of newly available codes, coding revisions to NCDs released separately, or coding feedback received.

Previous NCD coding changes appear in ICD-10 quarterly updates that can be found at: https://www.cms.gov/Medicare/Coverage/CoverageGenInfo/ICD10.html , along with other CRs implementing new policy NCDs. Edits to ICD-10 and other coding updates specific to NCDs will be included in subsequent quarterly releases and individual CRs as appropriate. No policy-related changes are included with the ICD-10 quarterly updates. Any policy-related changes to NCDs continue to be implemented via the current, longstanding NCD process. ( TN 10515 ) (CR12027)

10/2020 - This Change Request (CR) constitutes a maintenance update of ICD-10 conversions and other coding updates specific to NCDs. These NCD coding changes are the result of newly available codes, coding revisions to NCDs released separately, or coding feedback received.

Previous NCD coding changes appear in ICD-10 quarterly updates that can be found at: https://www.cms.gov/Medicare/Coverage/CoverageGenInfo/ICD10.html , along with other CRs implementing new policy NCDs. Edits to ICD-10 and other coding updates specific to NCDs will be included in subsequent quarterly releases and individual CRs as appropriate. No policy-related changes are included with the ICD-10 quarterly updates. Any policy-related changes to NCDs continue to be implemented via the current, longstanding NCD process. ( TN 10432 ) (CR12027)

12/2015 - This change request (CR) is the 3rd maintenance update of ICD-10 conversions/updates specific to national coverage determinations (NCDs). The majority of the NCDs included are a result of feedback received from previous ICD-10 NCD CR7818, CR8109, CR8197, CR8691, & CR9087. Some are the result of revisions required to other NCD-related CRs released separately that included ICD-10 coding. Implementation date: 01/04/2016 Effective date: 10/1/2015. ( TN 1580 ) (CR9252)

08/2015 - This change request (CR) is the 3rd maintenance update of ICD-10 conversions/updates specific to national coverage determinations (NCDs). The majority of the NCDs included are a result of feedback received from previous ICD-10 NCD CR7818, CR8109, CR8197, CR8691, & CR9087. Some are the result of revisions required to other NCD-related CRs released separately that included ICD-10 coding.

These updates do not expand, restrict, or alter existing coverage policy. Implementation date: 01/04/2016 Effective date: 10/1/2015. ( TN 1537 ) (CR 9252)

05/2014 - CMS translated the information for this policy from ICD-9-CM/PCS to ICD-10-CM/PCS according to HIPAA standard medical data code set requirements and updated any necessary and related coding infrastructure. These updates do not expand, restrict, or alter existing coverage policy. Implementation date: 10/06/2014 Effective date: 10/1/2015. ( TN 1388 ) ( TN 1388 ) (CR 8691)

09/2012 - CMS translated the information for this policy from ICD-9-CM/PCS to ICD-10-CM/PCS according to HIPAA standard medical data code set requirements and updated any necessary and related coding infrastructure. These updates do not expand, restrict, or alter existing coverage policy. Implementation date: 01/07/2013 Effective date: 10/1/2015. ( TN 1122 ) ( TN 1122 ) (CR 7818)

06/2001 - Added iron sucrose injection for first line treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental erythropoeitin therapy. Effective and implementation dates 10/01/2001. ( TN 139 ) (CR 1682)

11/2000 - Added sodium ferric gluconate complex in sucrose injection for first line treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental erythropoeitin therapy. Effective and implementation dates 12/01/2000. (TN 130) (CR 1322)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 110.10

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 110.10

What does NCD 110.10 cover?

Effective December 1, 2000, Medicare covers sodium ferric gluconate complex in sucrose injection as a first line treatment of iron deficiency anemia when furnished intravenously to patients undergoing chronic hemodialysis who are receiving supplemental erythropoeitin therapy. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 110.10 take effect?

The current version (1) is effective 10/01/2001, implemented 10/01/2001, published in transmittal 139. This is the only published version.

Does a Local Coverage Determination override NCD 110.10?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.